American Well Corporation
NYSE:AMWLMedical - Healthcare Information Services
+$0.24 today
- Market cap
- $171.77M
- Beta
- 1.70
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$5.30
Volume 0.06M
Average 0.07M
AMWL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
American Well CorporationNYSE: AMWL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $12.38M fell 44.0% year over year, behind the -22.5% change in trailing-twelve-month research & development. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.
Context
- Research & development amounted to 29.2% of revenue in FY2025, down 4.6 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -44.0% toward the trailing-twelve-month pace of -22.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 72.86M USD
- Year-over-year change
- -15.3%
- 4-year CAGR
- -9.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.86M | -15.3% |
| FY2024 | 2024-12-31 | 86.07M | -18.7% |
| FY2023 | 2023-12-31 | 105.83M | -23.6% |
| FY2022 | 2022-12-31 | 138.49M | +29.9% |
| FY2021 | 2021-12-31 | 106.59M | — |
Research & Development vs competitors
How AMWL compares with its peers on the latest reported figures
- AMWL's LTM Mar 2026 research & development of $63.14M is the 4th highest of the 9 companies compared; the peer median is $54.54M.
- Its year-over-year change of -22.5% is the 7th highest of 9, against a peer median of -5.1%.
- Research & development amounts to 26.6% of revenue for AMWL, versus a peer median of 538.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $70.7M | -6.3% | +29.5% | — | |
| LTM Mar 2026 | $66.71M | -38.5% | -7.9% | — | |
| LTM Mar 2026 | $63.14M | -22.5% | -19.3% | 26.6% | |
| LTM Mar 2026 | $55.72M | +5.5% | +12.0% | 29327.4% | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $37.7M | -3.9% | — | 958.2% | |
| LTM Jun 2026 | $1.53K | +525.4% | -75.6% | 0.0% | |
| Peer median (excluding AMWL) | $54.54M | -5.1% | +4.8% | 538.3% | |
Competitors are the stored peer set for AMWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 252.79M | 277.19M | 259.05M | 254.36M | 249.33M |
| Cost of Revenue | 148.47M | 160.42M | 164.29M | 155.41M | 116.47M |
| Gross Profit | 104.32M | 116.77M | 94.76M | 98.95M | 132.86M |
| Gross Margin | 41.3% | 42.1% | 36.6% | 38.9% | 53.3% |
| Research & Development | 106.59M | 138.49M | 105.83M | 86.07M | 72.86M |
| Selling, General & Admin | 160.78M | 227.98M | 213.11M | 197.45M | 131.31M |
| Operating Expenses | 283.46M | 392.62M | 786.9M | 316.49M | 238.13M |
| Depreciation & Amortization | 16.09M | 26.17M | 31.51M | 32.98M | 33.96M |
| EBITDA | (166.07M) | (245.84M) | (224.15M) | (176.91M) | (60.57M) |
| EBITDA Margin | -65.7% | -88.7% | -86.5% | -69.6% | -24.3% |
| Operating Income | (179.15M) | (275.85M) | (692.14M) | (217.53M) | (105.27M) |
| Operating Margin | -70.9% | -99.5% | -267.2% | -85.5% | -42.2% |
| Interest Income | 120K | 6.12M | 19.42M | 10.76M | 3.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.01M) | 3.85M | 16.83M | 7.65M | 10.74M |
| Income Before Tax | (182.16M) | (272.01M) | (675.31M) | (209.89M) | (94.53M) |
| Pre-Tax Margin | -72.1% | -98.1% | -260.7% | -82.5% | -37.9% |
| Income Tax Expense | (5.38M) | 64K | 3.86M | 2.75M | 434K |
| Net Income | (176.33M) | (270.43M) | (675.16M) | (208.14M) | (95.7M) |
| Net Margin | -69.8% | -97.6% | -260.6% | -81.8% | -38.4% |
| EPS (Basic) | (13.88) | (19.68) | (47.50) | (13.88) | (5.96) |
| EPS (Diluted) | (13.88) | (19.68) | (47.50) | (13.88) | (5.96) |
| Weighted Avg Shares | 12.7M | 13.71M | 14.21M | 15M | 16.05M |
| Weighted Avg Shares (Diluted) | 12.7M | 13.71M | 14.21M | 15M | 16.05M |
American Well Corporation
NYSE:AMWL
Intrinsic Alpha fair value
Locked
Current Price
$11.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.